NIKKEI 225
39,667.07 +493.92 (+1.26%) HANG SENG
18,089.93 +17.03 (+0.09%) CRUDE OIL
81.07 +0.24 (+0.30%) GOLD FUTURES
2,312.00 -18.80 (-0.81%) DOW
39,165.75 +53.59 (+0.14%) Bitcoin GBP
48,364.63 -476.83 (-0.98%)
ANIP Jul 2024 75.000 call
| Previous close | 0.2500 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 0.3500 |
| Strike | 75.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.2500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 330 |
ZacksAlimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.
GlobeNewswireANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner
Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year® 2024 New Jersey Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth compa
BenzingaGenerics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
On Monday, ANI Pharmaceuticals Inc (NASDAQ:ANIP) agreed to acquire Alimera Sciences Inc (NASDAQ:ALIM) for $5.50 per share in cash and one non-tradable contingent value right (CVR) of up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. ANI will also repay $72.5 million of Alimera debt. The transaction, which values Alimera at approximately $381 million in upfront consideration, has been approved by both the ANI and Alimera Boards of Directors and is expecte
